BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34502522)

  • 21. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of circRNA-lncRNA-miRNA-mRNA Competitive Endogenous RNA Network as Novel Prognostic Markers for Acute Myeloid Leukemia.
    Cheng Y; Su Y; Wang S; Liu Y; Jin L; Wan Q; Liu Y; Li C; Sang X; Yang L; Liu C; Wang Z
    Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32751923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML.
    Ruvolo PP; Hu CW; Qiu Y; Ruvolo VR; Go RL; Hubner SE; Coombes KR; Andreeff M; Qutub AA; Kornblau SM
    EBioMedicine; 2019 Jun; 44():126-137. PubMed ID: 31105032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
    Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression and regulation of HOX genes and membrane proteins among different cytogenetic groups of acute myeloid leukemia.
    Wang H; Lin SY; Hu FF; Guo AY; Hu H
    Mol Genet Genomic Med; 2020 Sep; 8(9):e1365. PubMed ID: 32614525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Network-based sub-network signatures unveil the potential for acute myeloid leukemia therapy.
    Shi M; Wu M; Pan P; Zhao R
    Mol Biosyst; 2014 Dec; 10(12):3290-7. PubMed ID: 25313005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of prognostic genes in the acute myeloid leukemia microenvironment.
    Huang S; Zhang B; Fan W; Zhao Q; Yang L; Xin W; Fu D
    Aging (Albany NY); 2019 Nov; 11(22):10557-10580. PubMed ID: 31740623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CEBPE expression is an independent prognostic factor for acute myeloid leukemia.
    Li K; Du Y; Wei DQ; Zhang F
    J Transl Med; 2019 Jun; 17(1):188. PubMed ID: 31164135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of distinctive long noncoding RNA competitive interactions and a six-methylated-gene prognostic signature in acute myeloid leukemia with -5/del(5q) or -7/del(7q).
    Yin X; Huang S; Xu A; Fan F; Chen L; Sun C; Hu Y
    J Cell Biochem; 2020 Feb; 121(2):1563-1574. PubMed ID: 31535409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weighted Gene Coexpression Network Analysis Identifies Cysteine-Rich Intestinal Protein 1 (CRIP1) as a Prognostic Gene Associated with Relapse in Patients with Acute Myeloid Leukemia.
    Ye C; Ma S; Xia B; Zheng C
    Med Sci Monit; 2019 Oct; 25():7396-7406. PubMed ID: 31577790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study.
    Wagner S; Vadakekolathu J; Tasian SK; Altmann H; Bornhäuser M; Pockley AG; Ball GR; Rutella S
    Blood Adv; 2019 Apr; 3(8):1330-1346. PubMed ID: 31015209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia.
    Guo C; Gao YY; Ju QQ; Zhang CX; Gong M; Li ZL
    BMC Cancer; 2020 Sep; 20(1):841. PubMed ID: 32883226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34
    Wang YY; Chen WL; Weng XQ; Sheng Y; Wu J; Hao J; Liu ZY; Zhu YM; Chen B; Xiong SM; Chen Y; Chen QS; Sun HP; Li JM; Wang J
    Stem Cells Dev; 2017 Oct; 26(20):1460-1467. PubMed ID: 28810819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients.
    Noordermeer SM; Sanders MA; Gilissen C; Tönnissen E; van der Heijden A; Döhner K; Bullinger L; Jansen JH; Valk PJ; van der Reijden BA
    Blood; 2011 Nov; 118(20):5613-21. PubMed ID: 21937695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Over expression of brain and acute leukemia, cytoplasmic and ETS-related gene is associated with poor outcome in acute myeloid leukemia.
    Hasan SK; Patkar NV; Rajamanickam D; Gokarn A; Lucena-Araujo AR; Tembhare P; Bagal B; Kadam Amare P; Jain H; Gujral S; Sengar M; Subramanian PG; Khattry N
    Hematol Oncol; 2020 Dec; 38(5):808-816. PubMed ID: 32893896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic impact of abnormally expressed, long noncoding RNAs in acute myeloid leukemia: a meta-analysis.
    Shi J; Shi X; Dai RQ
    Hematology; 2020 Dec; 25(1):219-228. PubMed ID: 33346694
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
    Zappasodi P; Marbello L; Borlenghi E; Fumagalli M; Bernardi M; Fracchiolla N; Mancini V; Da Vià M; Ravano E; Cerqui E; Ferretti VV; Rocca B; Calvello C; Cazzola M; Castagnola C; Rossi G
    Ann Hematol; 2018 Nov; 97(11):2107-2115. PubMed ID: 30009341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.